Venus Concept EBITDA 2011-2026 | VERO

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Venus Concept

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-23.3 M	-24.2 M	-30.4 M	-9.91 M	-35.6 M	-27.9 M	-25.1 M	-16.7 M	-18.3 M	-19.7 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-9.91 M	-35.6 M	-23.1 M

Quarterly EBITDA Venus Concept

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-9.4 M	-8.95 M	-8.58 M	-	-7.06 M	-5.48 M	-6.78 M	-	-6.63 M	-5.53 M	-7.15 M	-	-11.2 M	-6.82 M	-6.34 M	-	-1.63 M	3.98 M	-5.53 M	-	-1.6 M	-6.29 M	-42.3 M	-	-6.34 M	-3.79 M	-1.54 M	-	-6.17 M	-5.04 M	-6.91 M	-	-4.47 M	-4.27 M	-4.28 M	-	-5.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
3.98 M	-42.3 M	-6.83 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Medical devices industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Abbott Laboratories ABT	9.49 B	$ 102.18	-0.67 %	$ 178 B	USA
AdaptHealth Corp. AHCO	473 M	$ 11.98	-0.42 %	$ 1.62 B	USA
Align Technology ALGN	753 M	$ 170.34	-0.15 %	$ 12.8 B	USA
Apyx Medical Corporation APYX	-5.79 M	$ 3.68	-0.14 %	$ 151 M	USA
GenMark Diagnostics, Inc. GNMK	-3.98 M	-	-	$ 1.77 B	USA
Alphatec Holdings ATEC	-4.64 M	$ 10.86	0.28 %	$ 1.63 B	USA
AxoGen AXGN	-1.19 M	$ 33.95	-1.44 %	$ 1.56 B	USA
Apollo Endosurgery APEN	-30.2 M	-	-	$ 475 M	USA
Butterfly Network BFLY	-65.5 M	$ 4.13	0.49 %	$ 874 M	USA
Acutus Medical AFIB	-11.5 M	-	-26.83 %	$ 2.62 M	USA
Avinger AVGR	-16.3 M	-	-20.74 %	$ 369 K	USA
Axonics Modulation Technologies AXNX	-53.2 M	-	-	$ 3.31 B	USA
Aziyo Biologics AZYO	-24.1 M	-	1.37 %	$ 20.5 M	USA
Allied Healthcare Products AHPI	-815 K	-	3.58 %	$ 2.21 M	USA
Obalon Therapeutics, Inc. OBLN	-9.8 M	-	-5.86 %	$ 30.6 M	USA
Bruker Corporation BRKR	437 M	$ 36.83	0.19 %	$ 5.49 K	USA
Boston Scientific Corporation BSX	4.98 B	$ 62.71	-0.18 %	$ 92.8 B	USA
BioSig Technologies BSGM	-67.6 M	-	37.08 %	$ 85.7 M	USA
ClearPoint Neuro CLPT	-23.4 M	$ 9.42	0.53 %	$ 267 M	USA
CONMED Corporation CNMD	120 M	$ 34.68	-0.32 %	$ 1.08 B	USA
Cytosorbents Corporation CTSO	-13.5 M	$ 0.6	2.92 %	$ 37.3 M	USA
Delcath Systems DCTH	898 K	$ 9.75	1.25 %	$ 349 M	USA
Cardiovascular Systems CSII	-32.1 M	-	0.15 %	$ 844 M	USA
Cutera CUTR	-148 M	-	-10.19 %	$ 1.99 M	USA
EDAP TMS S.A. EDAP	-17.9 M	$ 3.38	-0.44 %	$ 127 M	France
Electromed ELMD	10.7 M	$ 23.29	-	$ 197 M	USA
Edwards Lifesciences Corporation EW	1.42 B	$ 80.81	-0.3 %	$ 47.3 B	USA
FONAR Corporation FONR	9.84 M	$ 18.58	-0.05 %	$ 122 M	USA
CryoLife, Inc. CRY	23.2 M	-	-4.14 %	$ 702 M	USA
Dynatronics Corporation DYNT	-1.97 M	-	14.99 %	$ 929 K	USA
Globus Medical GMED	757 M	$ 87.99	0.08 %	$ 11.9 B	USA
Eargo EAR	-106 M	-	-	$ 10.2 M	USA
Helius Medical Technologies HSDT	-12.4 M	$ 1.96	5.52 %	$ 1.19 M	USA
Integra LifeSciences Holdings Corporation IART	70.8 M	$ 9.46	-0.73 %	$ 729 M	USA
Soliton, Inc. SOLY	-14.1 M	-	-1.42 %	$ 435 M	USA
Conformis CFMS	-42.2 M	-	-	$ 16.4 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	88.4 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	-8.53 M	-	0.03 %	$ 1.58 B	Israel
Inogen INGN	-9.55 M	$ 6.24	0.48 %	$ 166 M	USA
Inspire Medical Systems INSP	64.9 M	$ 56.41	2.58 %	$ 1.66 B	USA
Misonix, Inc. MSON	-15.9 M	-	-	$ 462 M	USA
IRIDEX Corporation IRIX	-2.05 M	$ 1.0	2.52 %	$ 16.9 M	USA
IRadimed Corporation IRMD	27.3 M	$ 95.03	-1.25 %	$ 1.21 B	USA
Neovasc NVCN	-31.1 M	-	-	$ 111 M	Canada
Integer Holdings Corporation ITGR	352 M	$ 85.96	-1.02 %	$ 2.99 B	USA
Second Sight Medical Products EYES	-27.1 M	-	-0.97 %	$ 54.4 M	USA
OrthoPediatrics Corp. KIDS	-18.1 M	$ 16.06	-	$ 377 M	USA
LENSAR LNSR	-21 M	$ 6.09	0.5 %	$ 72.8 M	USA